Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: blessedtobehere who wrote (50198)	2/8/2019 6:47:05 PM
From: jargonweary	3 Recommendations Recommended By bnutman diaperdaddy ladyPI Read Replies (1) \| Respond to of 63276

Seriously? You just get out of the penalty box and you post a message like that? Exercise a thimble full of discipline.

To: blessedtobehere who wrote (50198)	2/8/2019 7:10:07 PM
From: idahoranch1	Read Replies (2) \| Respond to of 63276

Not entirely true, the author of a post has 15 minutes to edit or erase their post. Thin thin Ice.

To: blessedtobehere who wrote (50198)	2/8/2019 7:10:11 PM
From: stockdoc77	2 Recommendations Recommended By ladyPI moochupecabra Read Replies (1) \| Respond to of 63276

"Ignore obvious stock manipulation, ignore obvious misleading information by analysts, ignore that we have absolutely no evidence that IMMU didn't meet FDA standards (other than the FDA said so)" I don't see "obvious" anything. Just a set of facts that leads you to that speculative conclusion. Also, the actual fact that the FDA issued a CRL means they did not meet FDA standards. If you think those standards are inappropriate and the company should have been given a pass anyway, that's your opinion, but not a fact of any sort, and without any evidentiary basis. In the history of the FDA, they have gotten into trouble many times for approving drugs that should not have been approved, but they have never been in trouble for not approving a drug which should have been. That is the risk benefit calculation that FDA officials make.